CDXS Related Analyst Ratings
-
Sidoti Starts Codexis, Inc. (CDXS) at Neutral
-
Piper Jaffray Upgrades Codexis, Inc. (CDXS) to Neutral, $2 Tgt
-
Credit Suisse Downgrades Codexis, Inc. (CDXS) to Neutral
-
Piper Jaffray Downgrades Codexis, Inc. (CDXS) to Underweight
-
Pacific Crest Downgrades Codexis, Inc. (CDXS) to Sector Perform
-
Baird Starts Codexis, Inc. (CDXS) at Neutral
-
UPDATE - UBS Upgrades Gevo (GEVO) to Buy on Recent Sell-off
-
Piper Jaffray Downgrades Codexis, Inc. (CDXS) to Neutral
-
Olympia Capital Markets Maintains a 'Buy' on Codexis (CDXS); Maxygen to Distribute Codexis Holding
-
Barclays on U.S. Clean Technology: Investing in Alternative Fuels; Starts Coverage on CLNE & CDXS
-
Barclays Initiates Coverage on Codexis, Inc.(CDXS) with an Equalweight
-
Piper Jaffray Upgrades Codexis (CDXS) to Overweight Ahead of Potential Commercialization
-
Credit Suisse Initiates Coverage on Codexis (CDXS) with an Outperform
-
Raymond James Initiates Coverage on Codexis (CDXS) with a Market Perform
-
Cantor Fitzgerald Starts Codexis (CDXS) at Buy; Enabling Pharma/Fuels Enzymes
-
Shares of Codexis (CDXS) are Trading 3.7% Higher; Piper & RBC Initiate Coverage
-
RBC Capital Initiates Coverage on Codexis (CDXS) with an Outperform
-
Piper Jaffray Initiates Coverage on Codexis (CDXS) with a Neutral; Timing Risk Balances Exciting Industrial Biotech Story
Back to CDXS Stock Lookup
